In a retrospective analysis, researchers compared survival outcomes and prognostic factors between patients with advanced-stage epithelial ovarian cancer who underwent hyperthermic intraperitoneal...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A retrospective cohort study compared the patient characteristics and postoperative outcomes of those with stage III or IV epithelial ovarian cancer who had same-day discharge following minimally invasive...
Researchers set out to determine whether short-course vaginal cuff brachytherapy regimen maintains quality of life and acceptable toxicity in patients with early-stage endometrial cancer.
A phase 3 trial subgroup analysis found that adding pembrolizumab to adjuvant chemotherapy may improve disease-free survival in patients with mismatch repair-deficient endometrial cancer, a population at...
A randomized trial found that radiation therapy alone provides better progression-free survival and fewer acute toxicities than chemoradiation for women with localized recurrent endometrial cancer.
New findings from the Women’s Health Initiative trials provide long-term insights into the effects of hormone therapy regimens on ovarian and endometrial cancer incidence and mortality.
Researchers developed a cross-sectional survey to understand the public and provider awareness of postmenopausal bleeding as a symptom of endometrial cancer.
Gynecologic oncologists currently lack risk models that can accurately predict an endometrial cancer diagnosis at the time of hysterectomy for endometrial intraepithelial neoplasia. To fill this gap,...
